105 patents currently held
40 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
22 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Of the 40 now held by other companies, 13 were conveyed to Autifony Therapeutics Limited in the filing they arrived in, and 27 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
65
Ending by 2030
Nov 2026
Next term end
73
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2032 · High confidence
Also notable
Ends no later than Aug 2034 · Medium confidence
Also notable
Ends Mar 2028 · High confidence
Also notable
Ends Jun 2027 · High confidence
Also notable
Ends Oct 2030 · High confidence
Also notable
Ends May 2034 · Medium confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Sep 2031 · High confidence
Modulation of Hepatitis B Virus (HBV) Expression
US 8,642,752
Cited by 64 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
B Cell Maturation Antigen (BCMA) BINDING PROTEINS
US 9,273,141
Cited by 42 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Container
US D701,456
Cited by 44 later US patents, top 25% of design patents granted in 2014 in our data. Protection runs to 2028.
Medicament Dispenser
US 8,511,304
Cited by 34 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Inhaler Device
US D769,438
Cited by 53 later US patents, top 25% of design patents granted in 2016 in our data. Protection runs to 2030.
Compositions and Methods for Modulating HBV Expression
US 9,145,558
The largest patent family in this portfolio, 6 related applications, renewed at every maintenance window due so far. Protection runs to 2034.
Combinations of a Muscarinic Receptor Antagonist and a BETA-2 Adrenoreceptor Agonist
US 9,750,726
The largest patent family in this portfolio, 8 related applications, renewed at every maintenance window due so far. Protection runs to 2030.
Novel Polymorphs and Salts
US 9,102,668
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Dec 2030 · High confidence
Cited by 27 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
conveyed to Autifony Therapeutics Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 6 to 9, 2026 · next Dec 6
- 2 fees due Feb 11 to 20, 2027 · next Feb 11
- 4 fees due Mar 1 to 29, 2027 · next Mar 1
- 2 fees due Apr 20, 2027
- 1 fee due May 5, 2027The maintenance fee for Methods for Selecting Protease Resistant Polypeptides (US 10,466,252) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Modified Antigens (US 9,200,044) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for Apparatus for Testing Samples Using Raman Radiation (US 9,261,404) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 2 fees due Sep 1, 2027
- 3 fees due Oct 19 to 28, 2027 · next Oct 19
- 3 fees due Nov 3 to 10, 2027 · next Nov 3
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 5 terms have ended since Aug 23, 2026
- Nov 17 US 9,187,192 Machine and Method for Pharmaceutical and Pharmaceutical-Like Product Assembly · term ended
- Nov 14 US 7,855,218 Novel Compounds · term ended
- Oct 20 US 8,746,242 Medicament Dispenser · surrendered on reissue
- Oct 11 US 10,350,238 Method of Treating Xerostomia · term ended
- Aug 28 US 10,058,551 Imidazolidinedione Derivatives · lapsed on the fee record
What they patent
The largest of its 73 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Label Set for an Inhalation Device | 4 in force | to Dec 2040 |
| 2-(AZAINDOL-2-YL)BENZIMIDAZOLES as PAD4 Inhibitors | 4 in force | to Jul 2032 |
| Modulation of Hepatitis B Virus (HBV) Expression | 4 in force | to Apr 2032 |
| Humanised anti-interleukin-18 antibody | 4 in force | to Jan 2029 |
| B Cell Maturation Antigen (BCMA) BINDING PROTEINS | 3 in force | to Aug 2034 |
| Compositions and Methods for Modulating HBV Expression | 3 in force | to Aug 2034 |
| 3 -Amino- Pyrazole Derivatives Useful Against Tuberculosis | 3 in force | to Oct 2031 |
| Combinations of a Muscarinic Receptor Antagonist and a BETA-2 Adrenoreceptor Agonist | 3 in force | to Nov 2030 |
| Novel Compounds | 3 in force | to Apr 2030 |
| Methods for Selecting Protease Resistant Polypeptides | 3 in force | to Feb 2030 |
| Container | 3 in force | to May 2029 |
| Chemical Process | 2 in force | to Aug 2033 |
| Inhaler Device | 2 in force | to Mar 2033 |
| Novel Polymorphs and Salts | 2 in force | to Sep 2031 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,713,518 | Capsule for a Powder Medicament In force · High confidence | In force | High confidence | |
| US 7,703,620 | Chain Linked Capsules In force · High confidence | In force | High confidence | |
| US 7,943,651 | Novel Compounds In force · High confidence | In force | High confidence | |
| US 10,703,814 | A Method of Treatment with Humanized ANTI-IL-18 Antibodies In force · High confidence | In force | High confidence | |
| US 8,511,304 | Medicament Dispenser In force · High confidence | In force | High confidence | |
| US 7,837,648 | Medicament Dispensing System In force · High confidence | In force | High confidence | |
| US 8,637,018 | Humanized ANTI-IL-18 Antibodies In force · High confidence | In force | High confidence | |
| US 9,499,617 | Humanized ANTI-IL-18 Antibodies In force · High confidence | In force | High confidence | |
| US 8,334,303 | Novel Polymorph of Mutilin In force · High confidence | In force | High confidence | |
| US 9,333,310 | Medicament Dispenser In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 105: 40 patents in force now held by others · 567 patents ended · 5 applications pending · 710 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.